Your browser is no longer supported. Please, upgrade your browser.
ICPT [NASD]
Intercept Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-13.75 Insider Own2.50% Shs Outstand22.64M Perf Week6.07%
Market Cap6.26B Forward P/E- EPS next Y-6.49 Insider Trans-58.49% Shs Float15.62M Perf Month11.76%
Income-283.20M PEG- EPS next Q-1.67 Inst Own68.60% Short Float17.75% Perf Quarter77.09%
Sales1.70M P/S3681.66 EPS this Y-262.50% Inst Trans21.81% Short Ratio4.16 Perf Half Y16.80%
Book/sh10.80 P/B25.60 EPS next Y13.60% ROA-114.10% Target Price410.33 Perf Year-17.28%
Cash/sh10.59 P/C26.11 EPS next 5Y9.97% ROE-180.30% 52W Range128.50 - 349.08 Perf YTD77.21%
Dividend- P/FCF- EPS past 5Y0.00% ROI-49.00% 52W High-20.81% Beta-
Dividend %- Quick Ratio16.20 Sales past 5Y- Gross Margin- 52W Low115.14% ATR17.08
Employees136 Current Ratio16.20 Sales Q/Q0.00% Oper. Margin- RSI (14)55.92 Volatility7.53% 6.40%
OptionableYes Debt/Eq0.00 EPS Q/Q-154.70% Profit Margin- Rel Volume1.05 Prev Close282.02
ShortableYes LT Debt/Eq0.00 EarningsMay 07 AMC Payout- Avg Volume665.93K Price276.45
Recom1.70 SMA20-0.83% SMA5020.15% SMA20024.91% Volume699,901 Change-1.98%
Mar-17-15Initiated MLV & Co Hold $273
Jan-28-15Reiterated Oppenheimer Outperform $499 → $375
Dec-04-14Initiated Robert W. Baird Outperform $258
Dec-03-14Reiterated FBR Capital Underperform $125 → $99
Nov-10-14Reiterated FBR Capital Underperform $172 → $125
Aug-15-14Initiated FBR Capital Underperform $172
Aug-12-14Reiterated RBC Capital Mkts Outperform $425 → $500
Jul-01-14Initiated RBC Capital Mkts Outperform $425
May-15-14Initiated Summer Street Research Buy $650
May-08-14Reiterated Oppenheimer Outperform $525 → $499
Mar-18-14Reiterated Needham Buy $320 → $500
Mar-14-14Reiterated Oppenheimer Outperform $360 → $525
Jan-10-14Reiterated Oppenheimer Outperform $94 → $360
Jan-10-14Reiterated Needham Buy $55 → $320
Oct-01-13Reiterated Oppenheimer Outperform $64 → $94
Aug-13-13Reiterated Needham Buy $40 → $55
Jul-11-13Reiterated Oppenheimer Outperform $60 → $64
Jan-16-13Reiterated Wedbush Outperform $25 → $46
Jan-04-13Reiterated Needham Buy $24 → $40
Nov-05-12Initiated Needham Buy $24
Mar-31-15 05:45PM  Stock Pops & Drops: DHI, ICPT, PCLN & DANG
12:41PM  Esperion Therapeutics Inc (ESPR), Intercept Pharmaceuticals Inc (ICPT): Visium and OrbiMeds Recent Activity in Biotech at Insider Monkey
09:23AM  Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock at noodls
09:14AM  Intercept Prices 1.2M Shares, Proceeds To Be ~$338.4M
09:13AM  Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock GlobeNewswire
08:51AM  Genfit's French Fans Fume Following Failure of Fatty Liver Drug at TheStreet
07:51AM  Early movers: MRH, JCI, DHI, PHG, TEVA, CVC & more at CNBC
06:48AM  Intercept Pharmaceuticals Announces Proposed Offering of Common Stock at noodls
06:24AM  Intercept Pharmaceuticals Announces Proposed Offering of Common Stock GlobeNewswire
Mar-28-15 09:10AM  Insiders Join the Selling Party as Markets Post Steep Drop at 24/7 Wall St.
Mar-27-15 03:30PM  Genfit sinks 31%, but CEO defends liver drug results at CNBC
02:20PM  Drug trial setbacks
01:06PM  Genfit's Loss Is Gain For Intercept Pharmaceuticals
09:40AM  Genfit Tortures Fatty Liver Drug to Extract Positive Results From Failed Study at TheStreet
Mar-26-15 06:07PM  Nasdaq stocks posting largest percentage increases AP +8.46%
02:53PM  GenFit NASH Data Drives Up Rival Intercept at Investor's Business Daily
12:02PM  Healthcare Hedge Fund Orbimeds Top Picks and New Move at Insider Monkey
Mar-24-15 07:43AM  Why Intercept Might Be A Better Bet Than Biogen Right Now
Mar-20-15 09:28AM  What Were Trading
08:59AM  Stock Futures Up, Dollar Mixed; Nasdaq Zeros In On Fresh High at Investor's Business Daily
06:28AM  Intercept Announces New Data Analyses From FLINT Trial of Obeticholic Acid in NASH at noodls
05:58AM  Intercept Announces New Data Analyses From FLINT Trial of Obeticholic Acid in NASH GlobeNewswire
Mar-18-15 04:10PM  Is Intercept The Next Biotech To Break Out?
Mar-17-15 05:40AM  Coverage initiated on Intercept Pharma by MLV & Co
Mar-16-15 07:00PM  Lightning Round: The downgrade was wrong on this at CNBC
02:57PM  Intercept Pharmaceuticals Revisits $300 For The First Time In 7 Months
Mar-13-15 01:19PM  Biotech bull case: MNK & ICPT
Mar-11-15 09:58AM  Genfit's Fatty Liver Drug Study Results Are Coming. Here's What You Need to Know. at TheStreet +6.14%
Mar-10-15 01:04PM  INTERCEPT PHARMACEUTICALS INC Financials
Mar-09-15 03:32PM  Intercept Pharmaceuticals Announces 2014 Financial Results at noodls
02:34PM  Three Reasons to Fear Biotech Stocks Right Now at Barrons.com
Mar-02-15 10:48AM  Intercept Pharma (ICPT) Earnings Report: Q4 2014 Conference Call Transcript at TheStreet
07:45AM  Intercept Pharmaceuticals (ICPT) Loss Narrows in Q4 - Tale of the Tape
07:07AM  Q4 2014 Intercept Pharmaceuticals Inc Earnings Release - Before Market Open
06:41AM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition
06:25AM  Intercept to Report Full Year 2014 Financial Results on March 2 and Present at Upcoming Conferences at noodls
06:21AM  Intercept misses 4Q profit forecasts AP
06:00AM  Intercept Pharmaceuticals Announces 2014 Financial Results GlobeNewswire
Feb-28-15 08:01PM  Intercept Pharmaceuticals (ICPT): Will It Miss Q4 Earnings? - Analyst Blog Zacks
Feb-25-15 06:06AM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements an EDGAR Online
Feb-23-15 06:00AM  Intercept to Report Full Year 2014 Financial Results on March 2 and Present at Upcoming Conferences GlobeNewswire
Feb-19-15 04:27PM  Intercept Announces Promotion of Lisa Bright to Chief Commercial & Corporate Affairs Officer GlobeNewswire
Feb-17-15 02:56PM  One ETF Gets a Lift From Rosetta Genomics ETF Trends
Feb-10-15 04:05PM  Intercept Pharmaceuticals Announces Completion of Public Offering and Exercise of Option to Purchase Additional Shares GlobeNewswire
Feb-06-15 09:25AM  Intercept Pharmaceuticals (ICPT) Jumps: Stock Adds 9.5% - Tale of the Tape Zacks
06:01AM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events EDGAR Online
Feb-04-15 07:34PM  Intercept Pharmaceuticals Announces Pricing of Public Offering GlobeNewswire
Feb-03-15 04:10PM  Intercept Pharmaceuticals Announces Proposed Public Offering of Common Stock GlobeNewswire
Jan-30-15 05:13PM  Intercept absolutely a buy: Pro CNBC +17.77%
04:54PM  Intercept Pharmaceuticals' OCA Now Breakthrough Therapy - Analyst Blog Zacks
04:50PM  Another absolutely wild day on Wall Street Yahoo Finance Contributors
04:41PM  Intercept Jumps on Breakthrough Status for Liver Treatment at Bloomberg
02:37PM  Intercept Pharmaceuticals -- Where Are The Mega Millions? at Forbes
06:01AM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
06:00AM  This ETF Should Like the Intercept Pharma News ETF Trends
Jan-29-15 04:05PM  Intercept Receives Breakthrough Therapy Designation From FDA for Obeticholic Acid for Nonalcoholic Steatohepatitis (NASH) With Liver Fibrosis GlobeNewswire
Jan-22-15 01:38PM  Deutsche Bank: No Big Move In FY15 For Intercept Pharmaceuticals Benzinga
Jan-12-15 09:26AM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclo EDGAR Online
08:00AM  Intercept Provides 2014 Year-End Update and Planned 2015 Milestones GlobeNewswire
Jan-07-15 04:05PM  Intercept to Present at the J.P. Morgan 33rd Annual Healthcare Conference GlobeNewswire
Jan-06-15 11:20AM  Gilead Acquires Drug Program For Fatty Liver Disease at Investor's Business Daily -9.60%
10:23AM  Gilead Sciences: Looking Beyond Hepatitis C at Barrons.com
Dec-29-14 03:47PM  Russell 1000's winners and losers CNBC
08:34AM  Biggest stock movers of 2014 CNBC
06:00AM  Biotech-Twitter 2014: A Look Back at the Biotech Year Through the Twitter Lens at TheStreet
Dec-23-14 11:17AM  Biotech Bull Markets and Billion-Dollar Valuations Yahoo Finance Contributors -6.64%
Dec-05-14 06:01AM  Intercept Announces Publication of Meta-Analysis From the Global PBC Study Group in Gastroenterology GlobeNewswire
Dec-03-14 04:31PM  Record territory again for the Dow Industrials Yahoo Finance Blogs
Nov-25-14 06:05AM  Intercept to Present at Upcoming Investor Conferences GlobeNewswire
05:51AM  Why Intercept Pharmaceuticals (ICPT) Could Be Positioned for a Slump Zacks
Nov-17-14 06:01AM  Intercept Pharmaceuticals Appoints Lisa Bright as Head of Europe GlobeNewswire
Nov-14-14 03:16PM  Intercept CEO: NASH epidemic of liver disease CNBC
06:00AM  Biotech Stock Mailbag: Spectrum, Intercept, Orexigen, Amarin, MannKind at TheStreet
Nov-12-14 04:42PM  A ho-hum day in the markets as stocks open weaker, but recover to close mixed... Yahoo Finance Blogs -5.87%
10:00AM  Intercept Pharmaceuticals (ICPT) Is Weak On High Volume Today at TheStreet
Nov-11-14 12:50PM  Conatus Pharmaceuticals (CNAT): Will Loss Narrow in Q3? Zacks
Nov-10-14 06:59PM  Genfit: This disease may affect 12% of US adults at CNBC
05:50PM  Big pharma's liver battle CNBC
04:28PM  Major averages start the week where they left offhigher Yahoo Finance Blogs
04:03PM  Intercept Pharmaceuticals' Shares Crash on FLINT Results Zacks
02:58PM  Intercept Seen as Poster-boy for Possible Biotech Bubble at TheStreet
Nov-08-14 12:00PM  Intercept Pharmaceuticals Below $180: Mega Millions Vanish at Forbes
08:01AM  Intercept Announces Additional Data for OCA in Primary Biliary Cirrhosis GlobeNewswire
Nov-07-14 06:08PM  Nasdaq stocks posting largest percentage decreases AP -30.12%
04:36PM  Stock Movers: Why These 4 Medical Stocks Dived Today at Investor's Business Daily
04:28PM  Another lackluster session for major equities Yahoo Finance Blogs
01:38PM  Midday Losers From November 7: Roka Bioscience, Salix Pharmaceuticals, Intercept Pharmaceuticals, Extended Stay America Benzinga
12:35PM  Midday movers: Allergan, Freshpet, Transocean & more at CNBC
12:15PM  Drug companies Salix, Intercept reeling after earnings, drama at MarketWatch
11:58AM  Stocks to watch ahead of liver disease conference at CNBC
07:07AM  Q3 2014 Intercept Pharmaceuticals Inc Earnings Release - Before Market Open CCBN
06:02AM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclo EDGAR Online
05:04AM  Intercept misses 3Q profit forecasts AP
Nov-06-14 07:05PM  FLINT Trial in NASH Published in The Lancet GlobeNewswire
06:31PM  Intercept Liver Drug Needs Safety Review, Researchers Say at Bloomberg
05:22PM  INTERCEPT PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
03:02PM  Will Intercept Pharmaceuticals' (ICPT) Q3 Loss Narrow? Zacks
Oct-31-14 06:01AM  Intercept to Report Third Quarter 2014 Results on November 7 and Present at Upcoming Conferences GlobeNewswire
Oct-23-14 04:04PM  Here's where to put your money to work, pros say at CNBC
02:04PM  Stock pickers shopping list CNBC
Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics to treat chronic liver and intestinal diseases utilizing its proprietary bile acid chemistry. It primarily develops obeticholic acid (OCA), a bile acid analog that completed Phase III clinical trial for the treatment of primary biliary cirrhosis; is in Phase III clinical trial for the treatment of nonalcoholic steatohepatitis; is in Phase 2 clinical trial for primary sclerosing cholangitis; and is in Phase I clinical trial for the treatment of biliary atresia. The company's product candidates in preclinical stage include INT-767, an orally administered dual FXR and TGR5 agonist for the treatment of fibrosis; and INT-777, an orally administered TGR5 agonist used in treating type 2 diabetes. Intercept Pharmaceuticals, Inc. was founded in 2002 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Duncan Barbara GayleChief Financial OfficerMar 27Sale289.821,000289,81716,264Apr 01 10:00 AM
SILVERSTEIN JONATHANDirectorMar 26Sale286.75157,20045,076,4421,120,324Mar 30 03:59 PM
ORBIMED ADVISORS LLCDirectorMar 26Sale286.75157,20045,076,4421,120,324Mar 30 03:58 PM
ORBIMED ADVISORS LLCDirectorMar 25Sale270.232,800756,6441,277,524Mar 25 07:28 PM
SILVERSTEIN JONATHANDirectorMar 25Sale270.232,800756,6441,277,524Mar 25 07:34 PM
SILVERSTEIN JONATHANDirectorMar 24Sale272.0045,60012,402,9951,280,324Mar 25 07:34 PM
ORBIMED ADVISORS LLCDirectorMar 24Sale272.0045,60012,402,9951,280,324Mar 25 07:28 PM
ORBIMED ADVISORS LLCDirectorMar 23Sale275.18159,40043,863,0671,325,924Mar 25 07:28 PM
SILVERSTEIN JONATHANDirectorMar 23Sale275.18159,40043,863,0671,325,924Mar 25 07:34 PM
WILLIAMS NICOLEDirectorMar 20Option Exercise9.829739,5571,935Mar 24 09:00 PM
WILLIAMS NICOLEDirectorMar 20Sale305.36973297,115962Mar 24 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentMar 16Option Exercise10.403,50036,40022,296Mar 18 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentMar 16Sale286.903,5001,004,14018,796Mar 18 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentMar 12Option Exercise8.675,00043,33423,796Mar 16 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentMar 12Sale285.995,0001,429,93818,796Mar 16 09:00 PM
VEITINGER KLAUS R DRDirectorMar 10Option Exercise21.503918,4072,557Mar 12 09:00 PM
VEITINGER KLAUS R DRDirectorMar 10Sale262.06391102,4652,166Mar 12 09:00 PM
VEITINGER KLAUS R DRDirectorFeb 24Option Exercise21.5063213,5882,798Feb 26 09:00 PM
VEITINGER KLAUS R DRDirectorFeb 24Sale222.50632140,6202,166Feb 26 09:00 PM
WILLIAMS NICOLEDirectorFeb 20Option Exercise9.829749,5671,936Feb 24 09:00 PM
WILLIAMS NICOLEDirectorFeb 20Sale216.00974210,384962Feb 24 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentFeb 17Option Exercise9.368,79482,28223,442Feb 19 09:02 PM
Shapiro DavidCMO and EVP - DevelopmentFeb 17Sale209.414,646972,92118,796Feb 19 09:02 PM
VEITINGER KLAUS R DRDirectorFeb 10Option Exercise21.502335,0102,399Feb 12 09:00 PM
VEITINGER KLAUS R DRDirectorFeb 10Sale195.5223345,5562,166Feb 12 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentJan 30Option Exercise9.487,50071,06722,148Feb 03 09:00 PM
Regan Daniel PaulChief Commercial OfficerJan 30Option Exercise37.699,847371,13311,111Feb 03 09:01 PM
Regan Daniel PaulChief Commercial OfficerJan 30Sale201.079,8471,979,9631,264Feb 03 09:01 PM
Shapiro DavidCMO and EVP - DevelopmentJan 30Sale205.847,5001,543,83214,648Feb 03 09:00 PM
WILLIAMS NICOLEDirectorJan 20Option Exercise9.829739,5572,438Jan 22 09:00 PM
WILLIAMS NICOLEDirectorJan 20Sale151.32973147,2341,465Jan 22 09:00 PM
VEITINGER KLAUS R DRDirectorJan 12Option Exercise21.502335,0102,399Jan 14 09:00 PM
VEITINGER KLAUS R DRDirectorJan 12Sale150.0123334,9522,166Jan 14 09:00 PM
Duncan Barbara GayleChief Financial OfficerJan 05Sale176.4914124,88417,264Jan 07 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentJan 05Sale172.63664114,62714,648Jan 07 09:01 PM
Pruzanski MarkCEO & PresidentJan 05Sale176.4946181,360491,032Jan 07 09:02 PM
Regan Daniel PaulChief Commercial OfficerJan 05Sale176.4914625,7671,264Jan 07 09:03 PM
Duncan Barbara GayleChief Financial OfficerJan 02Option Exercise31.901,00031,90018,405Jan 05 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentJan 02Sale158.7137659,67515,312Jan 05 09:01 PM
Duncan Barbara GayleChief Financial OfficerJan 02Sale156.401,000156,40017,405Jan 05 09:00 PM
Benatti LucaDirectorDec 15Buy139.86800111,8881,292Dec 15 09:00 PM
VEITINGER KLAUS R DRDirectorDec 10Option Exercise21.502335,0102,399Dec 12 09:00 PM
VEITINGER KLAUS R DRDirectorDec 10Sale144.1623333,5892,166Dec 12 09:00 PM
Pruzanski MarkCEO & PresidentNov 19Option Exercise8.736,71658,603486,625Nov 20 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentNov 17Option Exercise10.404,00041,60018,855Nov 19 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentNov 17Sale158.824,790760,73014,065Nov 19 09:00 PM
AKKARAJU SRINIVASDirectorNov 12Buy167.192,000334,3877,642Nov 13 09:32 AM
AKKARAJU SRINIVASDirectorNov 11Option Exercise21.502,50053,7505,642Nov 13 09:32 AM
VEITINGER KLAUS R DRDirectorNov 10Option Exercise21.502335,0102,399Nov 12 09:00 PM
VEITINGER KLAUS R DRDirectorNov 10Sale175.9523340,9962,166Nov 12 09:00 PM
Pruzanski MarkCEO & PresidentNov 03Option Exercise8.6710,00086,667489,909Nov 05 09:00 PM
Pruzanski MarkCEO & PresidentNov 03Sale259.4110,0002,594,124479,909Nov 05 09:00 PM
VEITINGER KLAUS R DRDirectorOct 10Option Exercise21.503918,4072,557Oct 15 09:00 PM
VEITINGER KLAUS R DRDirectorOct 10Sale223.6539187,4472,166Oct 15 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentOct 02Sale233.97832194,66414,855Oct 03 09:00 PM
Pruzanski MarkCEO & PresidentOct 01Option Exercise8.6710,00086,667489,909Oct 03 09:00 PM
Duncan Barbara GayleChief Financial OfficerOct 01Option Exercise31.901,00031,90017,107Oct 03 09:01 PM
Shapiro DavidCMO and EVP - DevelopmentOct 01Option Exercise10.404,00041,60019,875Oct 03 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentOct 01Sale231.174,188968,13015,687Oct 03 09:00 PM
Duncan Barbara GayleChief Financial OfficerOct 01Sale233.121,000233,11916,107Oct 03 09:01 PM
Pruzanski MarkCEO & PresidentOct 01Sale228.8210,0002,288,187479,909Oct 03 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentSep 15Option Exercise10.404,00041,60018,253Sep 17 09:04 PM
Shapiro DavidCMO and EVP - DevelopmentSep 15Sale281.194,0001,124,75114,253Sep 17 09:04 PM
VEITINGER KLAUS R DRDirectorSep 10Option Exercise21.503918,4072,557Sep 12 09:00 PM
VEITINGER KLAUS R DRDirectorSep 10Sale280.50391109,6762,166Sep 12 09:00 PM
Pruzanski MarkCEO & PresidentSep 02Option Exercise8.6710,00086,667485,042Sep 04 09:11 PM
Pruzanski MarkCEO & PresidentSep 02Sale286.4910,0002,864,883475,042Sep 04 09:11 PM
Shapiro DavidCMO and EVP - DevelopmentAug 27Option Exercise8.6710,00086,66724,253Aug 29 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentAug 27Sale293.9310,0002,939,28614,253Aug 29 09:00 PM
ORBIMED ADVISORS LLCDirectorAug 26Sale300.0761,25818,381,5881,485,324Aug 27 09:05 PM
SILVERSTEIN JONATHANDirectorAug 26Sale300.0761,25818,381,5881,485,324Aug 27 09:06 PM
SILVERSTEIN JONATHANDirectorAug 25Sale295.5950,00014,779,4991,546,582Aug 27 09:06 PM
ORBIMED ADVISORS LLCDirectorAug 25Sale295.5950,00014,779,4991,546,582Aug 27 09:05 PM
WILLIAMS NICOLEDirectorAug 25Sale295.082,433717,9191,465Aug 27 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentAug 15Option Exercise10.404,00041,60019,027Aug 15 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentAug 15Sale291.494,7741,391,56814,253Aug 15 09:00 PM
SILVERSTEIN JONATHANDirectorAug 14Sale299.8260,00017,989,2071,596,582Aug 18 09:13 PM
ORBIMED ADVISORS LLCDirectorAug 14Sale299.8260,00017,989,2071,596,582Aug 18 09:07 PM
Adorini LucianoChief Scientific OfficerAug 12Option Exercise8.6711,03895,66319,151Aug 15 09:00 PM
Regan Daniel PaulChief Commercial OfficerAug 12Option Exercise37.698,124306,1949,534Aug 15 09:00 PM
VEITINGER KLAUS R DRDirectorAug 12Option Exercise21.503166,7942,482Aug 15 09:00 PM
Adorini LucianoChief Scientific OfficerAug 12Sale321.6211,0383,550,0788,113Aug 15 09:00 PM
Regan Daniel PaulChief Commercial OfficerAug 12Sale325.708,1242,645,9631,410Aug 15 09:00 PM
VEITINGER KLAUS R DRDirectorAug 12Sale345.62316109,2162,166Aug 15 09:00 PM
VEITINGER KLAUS R DRDirectorAug 11Option Exercise21.503918,4072,557Aug 12 09:00 PM
VEITINGER KLAUS R DRDirectorAug 11Sale238.72555132,4882,166Aug 12 09:00 PM
Fundaro PaoloDirectorAug 11Sale239.4932477,5958,803Aug 12 09:03 PM
Pruzanski MarkCEO & PresidentAug 01Option Exercise8.6710,00086,667485,042Aug 06 09:00 PM
Pruzanski MarkCEO & PresidentAug 01Sale226.7210,0002,267,198475,042Aug 06 09:00 PM
VEITINGER KLAUS R DRDirectorJul 10Option Exercise21.503918,4072,171Jul 11 09:00 PM
VEITINGER KLAUS R DRDirectorJul 10Sale219.1539185,6881,780Jul 11 09:00 PM
TALLARIGO LORENZODirectorJul 07Option Exercise9.822,00019,6452,000Jul 09 09:00 PM
TALLARIGO LORENZODirectorJul 07Sale243.062,000486,1100Jul 09 09:00 PM
Regan Daniel PaulChief Commercial OfficerJul 03Option Exercise37.691381,411Jul 08 09:00 PM
Regan Daniel PaulChief Commercial OfficerJul 03Sale250.0012501,410Jul 08 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentJul 02Sale247.65849210,25715,027Jul 03 09:01 PM
Shapiro DavidCMO and EVP - DevelopmentJul 01Option Exercise10.404,00041,60020,063Jul 03 09:01 PM
Pruzanski MarkCEO & PresidentJul 01Option Exercise8.6710,00086,667485,042Jul 03 09:01 PM
Shapiro DavidCMO and EVP - DevelopmentJul 01Sale244.144,1871,022,19515,876Jul 03 09:01 PM
Pruzanski MarkCEO & PresidentJul 01Sale250.6110,0002,506,121475,042Jul 03 09:01 PM